Products
Datopotamab Biosimilar Monoclonal Antibody (TROP-2) for Research
Pre-Made Datopotamab biosimilar, Whole mAb, Anti-TACSTD2 Antibody: Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Datopotamab deruxtecan is an antibody drug conjugate (ADC), composed of an humanised anti-TROP2 monoclonal antibody and MAAA 1181a, a derivative of exatecan, a DNA topoisomerase I inhibitor, being developed by Daiichi Sankyo for the treatment of solid tumours including non-small cell lung cancer and breast cancer .
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-134-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Datopotamab biosimilar, Whole mAb, Anti-TACSTD2 Antibody: Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 therapeutic antibody |
| INN Name | Datopotamab |
| Target | TACSTD2 |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Daiichi Sankyo |
| Conditions Approved | na |
| Conditions Active | Breast cancer;Non-small cell lung cancer |
| Conditions Discontinued | na |
| Development Tech | na |
About target - TACSTD2
1. Protein Tumor-associated calcium signal transducer 2
2. Gene TACSTD2
3. Organism Homo sapiens (Human)
Function
May function as a growth factor receptor.
